Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Atypical antipsychotics in the treatment of patients with a dual diagnosis of schizophrenia spectrum disorders and substance use disorders: the results of a randomized comparative study

Skryabin, V. Yu., Vinnikova, M. A., Ezhkova, E. V., Titkov, M. S., Bulatova, R. A. · 2021 · Journal of Addictive Diseases

Abstract

The article presents the results of a randomized comparative study of Aripiprazole and Quetiapine in the treatment of patients with a dual diagnosis: schizophrenia and substance use disorders. During the study, 90 of the 266 male patients were screened. Among them, 54 individuals (60%) had a previously established diagnosis of mental disorder and 36 patients (40%) had no established psychiatric diagnosis. They were randomly randomized into three groups of 30 patients, each receiving an antipsychotic: Aripiprazole at a dose of up to 20 mg daily, Quetiapine at a dose of up to 600 mg daily, or Haloperidol at a dose of up to 30 mg daily. The efficacy of Aripiprazole and Quetiapine was evaluated using the following scales: PANSS, BPRS, VAS, and Substance Craving Scale (SCS). Drug safety was assessed by the development of adverse events, serious adverse events, or adverse reactions. Study results demonstrated the efficacy of atypical antipsychotics in the three groups. Analysis of independent variables showed significant differences between Aripiprazole and Haloperidol in PANSS and BPRS scores by Visit 4, in VAS scores by Visit 3, and in SCS scores by Visit 2. Intergroup analysis of independent variables showed significant differences between Quetiapine and Haloperidol in PANSS, VAS, and SCS scores by Visit 4. Intergroup analysis of independent variables showed significant differences between Aripiprazole and Quetiapine in the VAS and SCS scores. The correlation analysis allowed dr…

Overview

Integrity signals

Registry

Crossref · 10.1080/10550887.2021.1905589

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 38 references

Research works printed but not linked: 11

  1. Janoutová J, 2016, Neuro Endocrinol Lett, 37, 1
  2. European Monitoring Centre for Drugs and Drug Addiction, 2019, European Drug Report
  3. Kirzhanova VV, 2017, The basic parameters of activity of narcological service in the Russian Federation in 2015-2016. A statistical compendium
  4. Ipser JC, 2015, Cochrane Database Syst Rev, 1, CD007505
  5. Unglaub W, 2003, Psychiatr Prax, 30, S121–4
  6. Brunetti M, 2012, Eur Rev Med Pharmacol Sci, 16, 1346
  7. Indave BI, 2016, Cochrane Database Syst Rev, 3, CD006306
  8. Maksimov VG., 2009, J Trudny`j Pacient, 9, 42
  9. Saffar SP, 2007, S D Med, 60, 439
  10. Overall E, 1988, Psychopharmacol Bull, 97
  11. Ivanets NN, 2001, Zhurnal Nevropatologii i Psixiatrii im. S.S.Korsakova, 8, 4

Cited by

See all 17

Metadata

Authors
Skryabin, V. Y., Vinnikova, M. A., Ezhkova, E. V., Titkov, M. S., & Bulatova, R. A.
Affiliations
  • Moscow Research and Practical Centre on Addictions of the Moscow Department of Healthcare, Moscow, Russia
  • Psychiatry and Psychotherapy Division, European Medical Centre, Moscow, Russia
Venue
Journal of Addictive Diseases
Published
2021-04-09
Volume
39
Issue
4
Pages
513-525
ISSN
  • 1055-0887 (ISSN-L)
  • 1545-0848
OpenAlex
W3142311157
Cited by
17
References
38
Citations by year
2026: 5 · 2025: 2 · 2024: 4 · 2023: 2 · 2022: 4
FWCI
1.79
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Addictive Diseases (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
Keywords
atypical antipsychotics, dual diagnosis, schizophrenia spectrum disorders, substance use disorders, aripiprazole, quetiapine, haloperidol, drug craving, symptom severity, adverse drug reactions, PANSS, Brief Psychiatric Rating Scale
MeSH terms
Aripiprazole, Quetiapine Fumarate, Adult, Haloperidol, Humans, Male, Middle Aged, Psychiatric Status Rating Scales, Schizophrenia, Antipsychotic Agents, Treatment Outcome, Diagnosis, Dual (Psychiatry), Substance-Related Disorders, Young Adult, Drug-Related Side Effects and Adverse Reactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Atypical antipsychotics in the treatment of patients with a dual diagnosis of schizophrenia spectrum disorders and substance use disorders: the results of a randomized comparative study. https://app.cochat.ai/papers/10.1080/10550887.2021.1905589
The paper
Skryabin, V. Y., Vinnikova, M. A., Ezhkova, E. V., Titkov, M. S., & Bulatova, R. A. (2021). Atypical antipsychotics in the treatment of patients with a dual diagnosis of schizophrenia spectrum disorders and substance use disorders: the results of a randomized comparative study. Journal of Addictive Diseases. https://doi.org/10.1080/10550887.2021.1905589

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.